secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001680367-24-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial
-------------------------------------------------------------------------

- Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.
- Cash and investments $105.3M as of June 30, 2024, down from $117.2M a year ago.
- SL-172154 in frontline HR-MDS: 67% ORR, 58% CR/marrow CR rate; median OS not reached.
- Randomized Part D enrollment initiated in frontline HR-MDS (1:1:1 vs AZA alone).
- Cash runway into 2026, beyond Phase 1 trial results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000038/0001680367-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000038/sttk-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001680367-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer